Baseline patient demographics, disease, and treatment characteristics
| . | N = 32 . |
|---|---|
| Mean age, median (range), y | 64 (44-78) |
| Sex, no. (%) | |
| Male | 20 (62.5) |
| Female | 12 (37.55) |
| ECOG performance status, no. (%) | |
| 0 | 16 (53) |
| 1 | 12 (40) |
| 2 | 2 (7) |
| Time since initial diagnosis, y (range) | 5.9 (1.2-13) |
| Prior regimens, median (range) | 6 (2-12) |
| Prior therapies, no. (%) | |
| Transplant | 21 (67) |
| Bortezomib | 31 (97; all but 2 bortezomib refractory) |
| Lenalidomide | 32 (100; all refractory) |
| Cytogenetics | |
| Hypodiploid | 3 |
| Hyperdiploid | 10 |
| Del(1) | 3 |
| Del(13) | 9 |
| Del(17p) | 5 |
| t(4;14) | 3 |
| t(11;14) | 5 |
| t(14;16) | 2 |
| . | N = 32 . |
|---|---|
| Mean age, median (range), y | 64 (44-78) |
| Sex, no. (%) | |
| Male | 20 (62.5) |
| Female | 12 (37.55) |
| ECOG performance status, no. (%) | |
| 0 | 16 (53) |
| 1 | 12 (40) |
| 2 | 2 (7) |
| Time since initial diagnosis, y (range) | 5.9 (1.2-13) |
| Prior regimens, median (range) | 6 (2-12) |
| Prior therapies, no. (%) | |
| Transplant | 21 (67) |
| Bortezomib | 31 (97; all but 2 bortezomib refractory) |
| Lenalidomide | 32 (100; all refractory) |
| Cytogenetics | |
| Hypodiploid | 3 |
| Hyperdiploid | 10 |
| Del(1) | 3 |
| Del(13) | 9 |
| Del(17p) | 5 |
| t(4;14) | 3 |
| t(11;14) | 5 |
| t(14;16) | 2 |
ECOG, Eastern Cooperative Oncology Group.